Updated recommendations on treatment of adolescents and children with chronic HCV infection

Overview

This policy brief focuses on the new recommendations on treatment of adolescents and children aged 3 years or older with chronic hepatitis C virus (HCV) infection.

The new treatment recommendations that extend the 2018 treat all recommendation for adults with chronic HCV infection to include adolescents and children down to 3 years, and to align the existing recommended pangenotypic direct-acting antiviral (DAA) regimens (SOF/DCV, SOF/VEL and G/P) for adults, to those for adolescents and children. This alignment is expected to simplify procurement, promote access to treatment among children in low- and middle-income countries and contribute to global efforts to eliminate the disease.